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DOPAL derived alpha-synuclein 
oligomers impair synaptic vesicles 
physiological function
N. Plotegher1,†, G. Berti1, E. Ferrari2,3, I. Tessari1, M. Zanetti4,5, L. Lunelli4,5, E. Greggio1, 
M. Bisaglia1, M. Veronesi6, S. Girotto6, M. Dalla Serra4, C. Perego7, L. Casella2 & L. Bubacco1
Parkinson’s disease is a neurodegenerative disorder characterized by the death of dopaminergic 
neurons and by accumulation of alpha-synuclein (aS) aggregates in the surviving neurons. The 
dopamine catabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL) is a highly reactive and toxic molecule 
that leads to aS oligomerization by covalent modifications to lysine residues. Here we show that 
DOPAL-induced aS oligomer formation in neurons is associated with damage of synaptic vesicles, and 
with alterations in the synaptic vesicles pools. To investigate the molecular mechanism that leads to 
synaptic impairment, we first aimed to characterize the biochemical and biophysical properties of the 
aS-DOPAL oligomers; heterogeneous ensembles of macromolecules able to permeabilise cholesterol-
containing lipid membranes. aS-DOPAL oligomers can induce dopamine leak in an in vitro model of 
synaptic vesicles and in cellular models. The dopamine released, after conversion to DOPAL in the 
cytoplasm, could trigger a noxious cycle that further fuels the formation of aS-DOPAL oligomers, 
inducing neurodegeneration.
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the prominent and progressive loss of 
dopaminergic neurons in the substantia nigra pars compacta (SNpc)1. Loss of these neurons suggests that this type 
of cells is particularly vulnerable to the pathological mechanisms leading to the disease. Based on this assumption, 
potential toxicity mechanisms associated with the presence of dopamine (DA) or DA catabolites in neurons, have 
been extensively investigated in the past2–4. In this context, the role of 3,4-dihydroxyphenylacetaldehyde (DOPAL) 
is of particular interest5. This catabolite is generated from DA by monoamine oxidase (MAO) and is highly reac-
tive and toxic. It presents an aldehyde moiety that drives DOPAL to react with the amino groups of proteins, and 
a catechol moiety, which can be oxidized to quinone and lead to polymerization. In healthy neurons, DOPAL is 
effectively detoxified by aldehyde dehydrogenase (ALDH), which converts DOPAL to 3,4-dihydroxyphenylacetic 
acid (DOPAC). Interestingly, DOPAL:DA ratios were found to be higher in PD brains than the corresponding 
ratios in control subjects6, and the cytosolic ALDH gene was found to be down regulated in PD brains7. Cytosolic 
ALDH is also differentially expressed among dopaminergic neurons, and the subpopulation of DA neurons which 
lack the enzyme is more vulnerable to neurodegeneration8. Exposure to ALDH inhibitors9, such as the fungicide 
benomyl10,11 or disulfiram12, causes DOPAL accumulation and have been associated with an increased risk to 
develop PD; ALDH-KO mice show a Parkinsonian phenotype, DA neuronal death and DOPAL accumulation13.
Another key player in the working hypothesis of this study is the presynaptic protein alpha-synuclein (aS). aS 
is the main constituent of Lewy bodies (LBs), which are inclusions composed of proteins and lipids found in PD 
brains14. Mutations in the aS gene and gene multiplications are associated to inherited PD forms15. The physiolog-
ical function of aS has been associated with neurotransmitter release16, synaptic vesicle trafficking17 and SNARE 
complex assembly18, but the details of its functions are yet to be elucidated. However, aS knock-out mice are viable 
and present only small alterations in DA level and release19.
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One relevant property of aS is its propensity to aggregate and to interact with DA20, leading to the formation of 
a heterogeneous ensemble of oligomers, which then convert to amyloid fibrils that are deposited in LBs. Different 
toxicity mechanisms, such as mitochondrial dysfunction21, autophagy impairment22 and membrane damage23, 
have been ascribed to the diverse forms of aS aggregates reported in the literature24. Therefore, it is still unclear 
which are the most relevant aggregates for the pathology, and what their primary toxic effect may be. The facts 
that aS (i) is highly concentrated at the presynaptic terminal, i.e. about 40 μ M25, (ii) has 15 lysines (Lys) in its 
sequence of 140 amino acids and (iii) is natively unfolded26, suggest that aS may be a target for DOPAL among 
synaptic proteins27. Concurrently, it was shown that DOPAL can cause aS oligomerization in vitro and in cell 
models4,28–31. Herein, starting from the detrimental effect caused by DOPAL-induced aS oligomerization on the 
function of synaptic vesicles, we investigated the structural and functional features of aS-DOPAL oligomers. This 
analysis allowed us to propose a mechanism by which synaptic vesicles could be damaged. In particular, we show 
that the oligomers can permeabilise cholesterol-containing lipid membranes mimicking synaptic vesicles in vitro, 
suggesting that the synergistic effect of aS and DOPAL accumulation in DA neurons may lead to the formation of 
oligomers able to negatively impact on the structure and function of synaptic vesicles.
Results
DOPAL-modified aS can damage cellular vesicles and affect their mobility in BE(2)-M17. 
DOPAL has previously been shown to induce the formation of aS oligomers in vitro4,28–31. To assess whether the 
DOPAL-induced oligomerization of aS may cause synaptic vesicle damage, we used a pH-sensitive fluorescent 
protein directly targeted to synaptic vesicles (synaptobrevin2-pHluorin), as a reporter in a total internal reflection 
fluorescence microscopy (TIRFM) experiment32,33 in live cells. Synaptobrevin2-pHluorin fluorescence intensity 
increases if pH becomes basic, i.e. if vesicle fusion and/or permeabilisation occurs. Fluorescence intensity varia-
tion was measured in BE(2)-M17 cells overexpressing aS, and treated with 100 μ M DOPAL, to monitor perme-
abilisation events. Normally, only vesicles fusing with the plasma membrane become fluorescent and then, after 
endocytosis, they are immediately switched off32. If DOPAL alters vesicles permeability, we expect an increase 
in the intensity, and in the persistence of the fluorescent signal associated with the vesicular structure. This vesi-
cle-targeted fluorescent probe allowed also to study vesicles mobility in live cells.
Synaptobrevin2-pHluorin and mCherry or aS-mCherry were co-transfected in BE(2)-M17 neuroblastoma 
cells (Fig. 1a). TIRFM was used to monitor changes in vesicles fluorescence intensity and in their mobility within 
150 nm from the plasma membrane. The variation in the cumulative distributions of the fluorescence intensity 
of the observed vesicles for cells overexpressing aS-mCherry (or mCherry as control) when untreated or upon 
24 h treatment with 100 μ M DOPAL was calculated (Fig. 1b). After 24 h of DOPAL treatment, the inflexion point 
of the curve reporting the cumulative distribution of the fluorescence intensity moves toward higher intensities 
values compared to time 0 in the aS-mCherry overexpressing cells, but not in control. This result suggests that 
DOPAL-modified aS or aS-DOPAL oligomers can cause a gradient driven efflux of H+ in vesicles that leads to 
an increase in pH, which is responsible for the increase in the fluorescence intensity. Consistently, the number of 
vesicles showing a high fluorescent value for the whole time span of the measure (i.e. the number of unchanged 
vesicles over a certain period of time) is increased in the aS overexpressing cells after DOPAL treatment (Fig. 1c).
Interestingly, there is also a significant reduction in the average distance covered by vesicles, in cells over-
expressing aS-mCherry after the DOPAL treatment compared to the control (Fig. 1d). No difference is present 
between mCherry and aS-mCherry overexpressing cells before DOPAL treatment, suggesting that the effect we 
measured depends on the synergic action of aS and DOPAL, likely through DOPAL-induced modification and 
oligomerisation of aS.
DOPAL affects synaptic vesicles pool in mice primary cortical neurons. An independent approach 
was used to verify that synaptic vesicles’ functionality is affected by the synergic effect of aS and DOPAL. We 
used mice primary cortical neurons that express endogenous aS25 and treated them at DIV14 with DOPAL. After 
overnight treatment with 0 uM, 20 uM or 50 uM DOPAL, neurons were prepared for TEM imaging and synapses 
were imaged (Fig. 2a). The relative distributions of the distances between vesicles and the active zone of the syn-
apses was measured as previously reported34 (Fig. 2b). From a quantitative comparison between the distributions 
corresponding to untreated and to 20 μ M or 50 μ M DOPAL treated neurons, DOPAL leads to a reduction in the 
readily releasable pool of synaptic vesicles, with an increase in the fraction of vesicles belonging to the resting pool 
(Fig. 2c). The counting of the individual vesicles in the TEM images also allowed analysis of the impact of DOPAL 
treatment and of the aS-DOPAL molecules on the average number of vesicles per synapse. The inflection point 
of the cumulative distribution of the number of vesicles per synapses is ~71 ± 3 for the untreated neurons and 
drops to 49 ± 2 and 38 ± 2 for the 20 μ M and 50 μ M DOPAL treated neurons, respectively, and it is decreasing in 
a [DOPAL]-dependent way (Fig. 2e,f).
aS-DOPAL oligomers are formed in BE(2)-M17, HEK293 cells and primary cortical neurons. To 
verify whether previously reported synaptic vesicles dysfunction in BE(2)-M17 and primary neurons could be 
associated with the presence of aS-DOPAL oligomers, BE(2)-M17 cells overexpressing aS tagged with mCherry 
(aS-mCherry) were treated with 100 μ M DOPAL. After 1, 18 or 24 h, cell lysates were subjected to the aminophe-
nylboronic acid (APBA) resin, which allowed the pull-down of DOPAL-modified proteins8. Both total cell 
lysates and the pull-down samples were analysed by western blot using an antibody against aS (Fig. 3a). Total 
cell lysate lanes show bands corresponding to oligomeric species when cells were treated with DOPAL, and the 
correspondent ABPA pull-down lanes show an increase in the detected aS, likely modified by DOPAL. These 
results suggest that aS monomers were covalently modified by DOPAL molecules, and formed oligomers upon 
DOPAL treatment. The formation of aS-DOPAL oligomers was not detected in an alternative cell line (HEK293T) 
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overexpressing aS fused with the fluorescent protein EGFP and treated with DOPAL (Fig. 3b) in spite of the pres-
ence of oligomeric species in the input.
Interestingly, the formation of aS-DOPAL oligomers also occurs in a more PD-relevant cellular environment 
in which aS is not overexpressed: in primary cortical neurons treated with 20 μ M or 50 μ M DOPAL and showing 
synaptic vesicles alterations previously described (Fig. 3c,d). The western blot analysis of aS level and oligomer-
isation showed that upon DOPAL treatment, monomeric aS was accumulated and aS-DOPAL oligomers were 
formed in a [DOPAL]-dependent manner. Altogether these results suggest that DOPAL can target both over-
expressed aS and endogenous aS, and it is able to induce aS oligomerization in immortalized cell lines, and in 
primary neurons. The presence of aS-DOPAL oligomers is likely associated with the impairment of homeostasis 
in synaptic vesicles observed in these models.
DOPAL modifies aS lysine residues both in cell models and in vitro. To characterize the molec-
ular level chemical modifications to aS induced by DOPAL in cell models, we set out to perform Liquid 
Chromatography-Mass Spectroscopy (LC-MS) experiments. We used HEK293T cells overexpressing aS-EGFP, 
and treated with 100 μ M DOPAL because in these conditions a higher yield in term of DOPAL-modified aS after 
ABPA resin pull-down was obtained.
We subsequently cut the band at 50 kDa as visualized by silver staining (i.e. where aS-EGFP is detected by 
western blot) in the APBA resin pull-down SDS-PAGE, and then digested the content of the band with pepsin. 
The resulting peptides were subjected to LC-MS analysis that showed that K6, K10, K12, K23, K32, K34, K43, 
K58, K60, K96 and K97 were modified by DOPAL (Table 1).
In parallel, we assessed the DOPAL-induced chemical modification to aS in vitro. To this end we incubated 
recombinant aS and DOPAL in a stoichiometric ratio of 1:20 in vitro for 5 h with and without the reducing agent 
Figure 1. DOPAL effect on vesicle trafficking in aS overexpressing cells. (a) Confocal images of BE(2)-M17 
cells transfected with mCherry or aS-mCherry and synapto-pHluorin. (b) Normalized fluorescence intensity/
number of vesicles cumulative graphs for mCherry and aS. Black and red traces refer to untreated cells, and 
cells treated with DOPAL 100 μ M for 24 hours. (c) Histograms express the ratio between fixed (see Methods for 
details) and total vesicles over a certain period of time, i.e. the number of vesicles showing a high fluorescent 
value for the whole time span of the measure, for mCherry or aS-mCherry overexpressing cells untreated or 
treated with 100 μ M for 24 hours. (d) Average distance covered by vesicles in cells overexpressing mCherry or 
aS-mCherry at time 0 and after 100 μ M DOPAL treatment at 24 hours. White and black stand for control cells 
and cells treated with 100 μ M DOPAL for 24 hours. Bars represent mean ± SEM from n = 25–30 cells from at 
least three independent experiments. Asterisks indicate statistical significance by two-way ANOVA (**p < 0.01, 
***p < 0.001).
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4Scientific RepoRts | 7:40699 | DOI: 10.1038/srep40699
Figure 2. DOPAL effect on synaptic vesicles in primary mouse neurons. (a) TEM images of mice primary 
neurons synapses not treated (CTRL) and treated with 20 μ M and 50 μ M DOPAL. (b) Frequency distribution 
of vesicles distance from the active zone of primary neurons in control, treated with 20 μ M and 50 μ M DOPAL 
(from left to right). Data were fitted with a three Gaussian function (OriginPro8). The dots represent the 
experimental points, the black continuous line is the best fit generated by sum of the contributing Gaussian 
curves (red continuous lines). (c) Grouped stack column plot of the percentage of area under curve of the three 
vesicle populations, representing the percentage of vesicles belonging to the ready-releasable (white), recycling 
(grey) and resting (black) pools in control neurons and in neurons treated with 20 μ M and 50 μ M DOPAL.  
(d) Summary of the parameters derived from the TEM images analysis: number of total vesicles, number of total 
synapses, average number of vesicles per synapse, and the value of the reduced Chi-Squared for fits with one, 
two, three and four Gaussian curves (OriginPro8), suggesting that the best fit is the one with three Gaussian 
curves. (e) Cumulative distributions of the number of vesicles per synapse show that the number of vesicles 
per synapse is higher in controls (full triangle) than in neurons treated with 20 μ M and 50 μ M DOPAL (empty 
triangles and empty circles, respectively). (f) Histograms representing the average inflection point values of 
the cumulative distribution of the number of vesicles/synapse showing a significant reduction after 20 μ M and 
50 μM DOPAL treatment. Bars represent mean ± SEM from n = 30–39 synapses from at least three independent 
experiments. Asterisks indicate statistical significance by two-way ANOVA (***p < 0.001).
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NaBH3CN, to mimic a possible contribution of reducing agents in the cell cytoplasm. Then the aS-DOPAL reac-
tion mixture was digested by pepsin and the resulting peptides were separated and analysed by LC-MS. In both 
non-reducing and reducing conditions, several possible modifications were considered, assuming that DOPAL 
could react with Lys residues of aS either through the catechol ring or the aldehyde group, as also proposed 
by others31,35. The results are summarized in Table 1 and compared to those obtained in cells and from other 
in vitro studies31. From these data we can infer that the reaction involving the aldehyde carbonyl is preferred, as 
in all experiments a mass increase compatible with the addition of a DOPAL-quinone through the aromatic ring 
(+ 148 amu on Lys 102) was observed only once. As expected, the presence of NaBH3CN changes the redox state 
of DOPAL adducts; in this condition, a 136 amu mass increase of lysine residues 6, 43, 58, 60 and 80 was observed 
(Fig. 4a). Furthermore, NaBH3CN seems to govern which Lys residues are more likely to be covalently modified 
by DOPAL. When aS and DOPAL were allowed to react without any reducing agent, a 134 amu mass increase was 
identified for Lys in positions 32 and 34. An increase of + 270 amu was observed for Lys residue in position 80, 
corresponding to a possible dimer of DOPAL.
In addition to covalent adducts with Lys residues, DOPAL is able to induce methionine oxidation to methio-
nine sulfoxide. Oxidation of Met in positions 1, 5 and 127 was observed in the experiments without NaBH3CN, 
while Met 127 was oxidized even in the presence of NaBH3CN. This result is only partially coherent with a 
Figure 3. aS-DOPAL oligomers are found in neuronal cell models upon DOPAL treatment. (a) Western blot 
analysis of BE(2)-M17 cells overexpressing aS-mCherry and treated with 100 μ M DOPAL for 1 hour, 18 hours 
or 24 hours. aS antibody detected aS monomers and oligomers (left) and after the pull-down with ABPA resin 
(right) the band showing monomeric aS modified by DOPAL is larger than the control after 18 or 24 hours 
treatment. (b) Western blot analysis of HEK293 cells treated with 100 μ M DOPAL showing DOPAL-induced 
aS oligomers at high molecular weight (left) and the pull-down with ABPA resin (right) show that DOPAL-
modified aS monomer is accumulated upon treatment. (c) Western blot of primary cortical neurons upon 
20 μM and 50 μ M DOPAL treatment show monomeric aS and aS-DOPAL oligomers accumulation. (d) ABPA 
resin pull-down from neuronal lysate of control and treated samples suggested that the accumulated monomeric 
aS is modified by DOPAL.
www.nature.com/scientificreports/
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recently published characterization of aS-DOPAL oligomers in which Follmer and colleagues found that the aS 
Lys modified by DOPAL are those at the N-terminus and in the NAC region of the protein, i.e. K10, K12, K21, 
K23, K32, K34 and K43 (Table 1)31.
HSQC-NMR measurements were then performed to follow the kinetics of the process, in an attempt to define 
the relative reactivity of the individual Lys residues in aS sequence. Given the high reactivity of DOPAL toward 
Lys27, the stoichiometric ratio was set between the protein and the aldehyde to 1:1 to slow down the reaction and 
improve time resolution. The resulting spectra are reported in Fig. 4b. Only some of the lysine residues modified 
by DOPAL seem to be involved in the reaction when DOPAL concentration is comparable to aS concentration. In 
particular, K12, one between K23 and K45, and one among K10, K34 and M127 (in the latter cases the peaks are 
too close to be discriminated) are the modified residues as detected by HSQC. Interestingly, HSQC also showed 
that V3, L8, S9 and S129 residues are affected by the reaction. For the first three, the peak shift may be due to the 
local changes induced by M5 oxidation and K10/K12 modification by DOPAL, while M127 oxidation may be 
responsible for the shift of the S129 peak.
DOPAL reaction with aS leads to the formation of aS oligomers in vitro. With the aim to define 
the in vitro structural and functional properties of the reaction products obtained from aS and DOPAL, and to 
define the possible mechanism(s) through which aS-DOPAL oligomers alter synaptic vesicles homeostasis, aS 
and DOPAL were reacted in vitro. 67 μ M recombinant purified aS was incubated with DOPAL in vitro for 5 h 
at pH 7.4 and 25 °C with a stoichiometric ratio of 1:20. Aliquots of the reaction mixture were collected at dif-
ferent time points (0, 30 min, 1, 2, 3, 4 and 5 h) and loaded onto a SDS-PAGE (Fig. 5a). The reaction produced a 
time-dependent intensity increase of the bands corresponding to oligomeric forms of aS. By increasing aS con-
centration to 300 μ M while maintaining a 1:20 aS:DOPAL stoichiometry, part of the aS-DOPAL reaction products 
were trapped in the SDS-page loading wells, being insoluble high molecular weight aggregates (Fig. 5b).
aS-DOPAL covalent oligomers form non-covalent aggregates in solution. An attempt was made 
to separate the different oligomeric forms of aS observed by electrophoresis by SEC (Fig. 5c). The elution profile 
of aS-DOPAL mixture in PBS pH 7.4 after 5 h reaction shows a high intensity peak eluting with the void volume 
of the column and a higher baseline, instead of the distribution of peaks corresponding to various aS oligomeric 
species. No peak at the retention time of about 25 min corresponding to monomeric aS was present. When SDS 
was added to the elution buffer, the peak eluting with the void volume of the column was reduced and broad 
peaks appeared at shorter retention time compared to monomeric aS. These results suggest that large peak in the 
void volume is constituted by non-covalent aS-DOPAL large oligomers, which are likely disassembled by the SDS 
present in the elution buffer. The non-covalent aS-DOPAL oligomers disassembly reveals the presence of smaller 
covalent aS-DOPAL oligomers that are shown as a ladder in the SDS-PAGE and in broad peaks with a reten-
tion time between 17.5 and 25 minutes when performing SEC. The high absorption due to the bound DOPAL 
hinders the possibility of using the chromatographic profile to quantify the relative amounts of aS, DOPAL and 
aS-DOPAL adducts at the end of the reaction.
Recombinant aS monomer 
modified by DOPAL – MS 
(Follmer et al.31)
Recombinant aS-DOPAL 
oligomers in reducing 
conditions (NaBH3CN) - MS
Recombinant 
aS-DOPAL 
oligomers - MS
DOPAL-modified aS 
monomers extracted 
from cells - MS
Recombinant aS-
DOPAL reaction – 
HSQC (Follmer et al.31)
Recombinant aS-
DOPAL reaction 
– HSQC
M1 + 16 + 16
M5 + 16 + 16 x x
K6 + 136 + 134
K10 + 134 + 134 x *
K12 + 148/+ 166/+ 168 + 270 x x
K21 + 148 no
K23 + 136 x **
K32 + 134 + 134 + 134/+ 136 no
K34 + 166/+ 168 + 134 + 134 *
K43 + 148 + 136 + 134
K45 **
K58 + 136 + 134 no
K60 + 136 + 134 x
K80 + 136 + 270 x no
K96 + 134 no
K97 + 136 no
K102 x no
M116 + 16 x
M127 + 16 + 16 x *
Table 1. Comparison among aS residues modified by the reaction with DOPAL identified by this group 
and others using MS and HSQC-NMR. *Means one or more among K10/K34/M127. **Means one or both 
between K23/K45.
www.nature.com/scientificreports/
7Scientific RepoRts | 7:40699 | DOI: 10.1038/srep40699
To define the morphology of the aS-DOPAL large oligomers, imaging experiments were performed on the 
elution peak collected at the void volume of the column. TEM imaging on the products of aS-DOPAL reaction at 
5 h confirmed that the oligomeric species are a heterogeneous ensemble mainly constituted by oligomers, some 
of which have a characteristic annular structure that was already observed for other aS oligomers36–39 (Fig. 5d).
DOPAL-modified aS cannot form amyloid fibrils. The time evolution of the products of the aS-DOPAL 
reaction was analysed by Thioflavin T (ThT) aggregation assay using unreacted aS as positive control. The kinetic 
analysis of the aggregation behaviour of aS control, as measured by the increase of ThT fluorescence intensity over 
time, showed a typical sigmoidal curve40. Conversely, when aS-DOPAL molecules were subjected to the same 
aggregation protocol, no increase in the ThT fluorescence signal was observed. This result suggests that DOPAL 
modifications of aS lead to the formation of DOPAL modified aS monomers and aS-DOPAL oligomers that do 
not convert into beta-sheet aS amyloid fibrils (Fig. 5e). The final products of the aggregation of aS-DOPAL mole-
cules resemble amorphous aggregates rather than the aS fibrils morphology obtained by aggregating monomeric 
aS alone when analysed by TEM. These results are in agreement with what was published by Follmer et al.31.
DOPAL-modified aS monomers and oligomers interact with and permeabilise cholesterol con-
taining lipid membranes. Synaptic vesicles are membranous structures that may be easily damaged by 
Figure 4. Mass spectra HSQC-NMR spectra of DOPAL modified aS. (a) In the left panel, MS/MS spectrum 
of the peak assigned to the VAEKTKE peptide (55–61 residues of aS) with the K58 residue bound to DOPAL, 
resulting in a 136 amu increase in peptide mass. This peptide was observed when aS reaction with DOPAL was 
performed in reducing conditions. The assignments of y and b ion series are reported (all are in mono-charged 
state). In the right panel, MS/MS spectrum of the peak assigned to the GVATVAEKTKEQVTNVG peptide 
(51–67 residues of aS) with the K58 and K60 residues bound to DOPAL, resulting in a 134 amu increase in 
peptide mass for each modification. This peptide was observed in aS-DOPAL in cell cultures experiments. The 
assignments of y and b ion series are reported (either in mono- or double-charged state). (b) Spectra overlap of 
15N-1H HSQC spectra recorded at 10 °C for a sample of 15N labelled aS (160.5 μ M) alone (red) or incubated with 
DOPAL for 1 month at 25 °C in a stoichiometric ratio of 1:1 (black).
www.nature.com/scientificreports/
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oligomers having the propensity to permeabilise lipid membranes. Given (i) the annular shape of the aS-DOPAL 
oligomers observed by TEM (Fig. 5d) similar to those able to permeabilise lipid membranes41 and (ii) the dam-
ages observed in synaptic vesicles in the experiments reported earlier in this manuscript, we investigated the 
ability of aS-DOPAL oligomers to permeabilise lipid membranes in vitro.
Figure 5. Biophysical and biochemical characterization of aS-DOPAL monomer and oligomers. (a) SDS-
PAGE of samples from the aS and DOPAL reaction performed at 25 °C for 5 hours collected at different time 
points. The reaction products were obtained reacting 67 μ M aS in a stoichiometric ratio of 1:20 with DOPAL.  
(b) SDS-PAGE showing the reaction products of 310 μ M aS in a stoichiometric ratio of 1:5 with DOPAL. 
(c) Size-exclusion chromatography of monomeric aS compared to the reaction products of 67 μ M aS in a 
stoichiometric ratio of 1:20 with DOPAL, which are large oligomers eluting in the void volume of the column. 
The graph also shows the chromatographic profile of aS-DOPAL oligomers in the presence of 0.1% SDS. The 
elution profile of aS-DOPAL oligomers changes in the presence of SDS and shows peaks at lower molecular 
weights further confirming that SDS can disaggregate the aS-DOPAL non-covalent oligomers into the ensemble 
of dimers, trimers and tetramers reported in panel a. (d) TEM image of aS-DOPAL oligomers showing annular 
shapes. (e) ThT kinetic of aS aggregation alone (full circles) shows the typical sigmoidal shape and lead to the 
formation of canonical amyloid fibrils. The aggregation process of aS-DOPAL molecules (empty squares) shows 
that they do not acquire a beta-sheet structure and the final products of the aggregation are not fibrils but 
amorphous aggregates.
www.nature.com/scientificreports/
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Since it was previously shown that monomeric aS is more active on negatively charged membranes composed 
by DOPE:DOPG = 1:1 42, we first performed experiments on planar lipid membranes (PLM) with this lipid com-
position, to test the permeabilising ability of aS-DOPAL oligomers. However, aS-DOPAL oligomers were unable 
to affect the stability of these membranes, and no changes in membrane permeability were observed at applied 
voltages ranging between − 150 mV and + 150 mV. The results of the PLM experiments radically changed when 
cholesterol was introduced (POPC:CHO = 1:1) (Fig. 6a). Currents were measured upon ± 40 V voltage applica-
tions and four levels of conductance were observed and analysed by fitting the conductance distribution (in nS) 
with a multi-Gaussian profile: c1 = 0.23 ± 0.02 nS; c2 = 0.57 ± 0.02 nS; c3 = 1.28 ± 0.02 nS and c4 = 1.9 ± 0.7 nS 
(R = 0.95) (Fig. 6b). This suggests that a heterogeneous population of oligomers may be responsible for the 
observed permeabilisation that occurs in cholesterol-containing membranes.
To further investigate aS-DOPAL oligomers permeabilising ability, we performed a calcein release assay (Fig. S1). 
Incubation of aS-DOPAL oligomers at different concentration (from 0.1 μ M to 20 μ M) with calcein-loaded 
POPC:CHO 1:1 liposomes (of an average diameter of 100 nm) did not lead to the expected increase in fluores-
cence intensity over time when calcein is released. To investigate whether the absence of calcein release was due 
to the pore selectivity, the absence of an applied voltage, or because the aS-DOPAL oligomers based pores were 
too small to allow the release of calcein from liposomes, a smaller and more relevant reporter molecule, DA, was 
chosen. An in vitro model for the study of DA release from liposomes mimicking synaptic vesicles was conceived: 
the hypothesis was that DA, which is smaller than calcein (153.2 vs. 622.6 g/mol), could leak out from the pores 
formed by aS-DOPAL oligomers. If proved, this permeabilisation effect could be a highly specific toxicity mech-
anism to be ascribed to aS-DOPAL oligomers, i.e. the damage of DA synaptic vesicles in dopaminergic neurons.
To detect DA leak from POPC:CHO = 1:1 vesicles, they were first loaded with DA in phosphate buffer pH 5.6 
to minimize DA autoxidation. Then, vesicles were resuspended in solution containing the DA oxidizing enzyme 
tyrosinase, and the DA-release from vesicles was monitored over time as Dopachrome formation (detected at 
450 nm) by tyrosinase. The results showed that the presence of 20 μ M aS-DOPAL oligomers induces a significant 
release of DA compared to the controls (Fig. 6b).
The permeabilisation properties of aS-DOPAL oligomers were then analysed in a cellular model. To test 
whether aS-DOPAL oligomers would localize at membranes in cells, BE(2)-M17 cells were treated with 2 μ M 
oligomers and their colocalisation with the plasma membrane marker E-cadherin was verified (Fig. 6c). Next, the 
permeabilisation of BE(2)-M17 cells plasma membrane (due to the treatment with aS-DOPAL oligomers) was 
measured, using propidium iodide as a marker (Fig. 6d). The obtained results suggest that oligomers maintain 
their ability to permeabilise the plasma membrane, which has a composition similar to that of synaptic vesicles, 
providing further support to the proposed role of as-DOPAL oligomers in damaging vesicles.
Structural and morphological characteristics of aS/DOPAL oligomers when localized at choles-
terol lipid membranes. A relevant issue previously discussed in the literature31 concerned the ability of the 
aS-DOPAL oligomers to acquire a specific secondary structure. To address this question, circular dichroism (CD) 
experiments were performed on aS-DOPAL oligomers in the presence of SDS or liposomes. The results showed 
that aS-DOPAL oligomers in the presence of SDS acquire an alpha-helical structure very similar to the secondary 
structure of monomeric aS in the same conditions (Fig. 6e). By measuring CD spectra of aS-DOPAL oligomers in 
the presence of SUVs, a very different result was obtained. In this latter case, the non-covalent interactions hold-
ing together aS-DOPAL covalent oligomers were maintained, and no variations in the CD signal of aS-DOPAL 
oligomers were observed. These results are in agreement with what was previously shown by Follmer et al.31 for 
the measurement performed in the presence of SDS, whereas aS-DOPAL molecules do not show any secondary 
structure in solution with SUVs in our experiment. This difference may be ascribed to the different lipid composi-
tion of SUVs and to the fact that Follmer measured aS-DOPAL monomer, while this study examined aS-DOPAL 
oligomeric ensemble of species.
Given the PLM and DA release results suggesting that aS-DOPAL oligomers interact with cholesterol contain-
ing lipid membranes in vitro, the morphology of these oligomers upon deposition on 50% DOPC-50% CHO lipid 
membranes was observed by atomic force microscopy (AFM). An example of the images obtained is shown in 
Fig. 6f, in which a 3D representation of aS-DOPAL oligomer is also reported. The observed structure is in agree-
ment with the results obtained in TEM experiments, and further supports that aS-DOPAL oligomers retain their 
pore-like structure upon interaction with lipid membranes.
Discussion
This study analysed how the DA catabolite DOPAL can covalently modify aS Lys, both in vitro and in neuronal 
models, leading to the formation of oligomeric species of aS which impair synaptic vesicles homeostasis. Two dif-
ferent strategies were used to study synaptic vesicles functionality in neuronal cells and in primary neurons in the 
presence of aS-DOPAL oligomers formed upon DOPAL treatment. The first relied on the overexpression of the 
fluorescent protein synapto-pHluorin targeted to the inside of synaptic vesicles in BE(2)-M17. The results suggest 
that the aS-DOPAL oligomers permeabilise the synaptic vesicles, and cause protons to leak out and raise the pH 
within the vesicles. At the same time, vesicle mobility was significantly affected. The second approach was based 
on TEM quantification of synaptic vesicles in primary neurons treated with DOPAL, in which the endogenous 
aS is sufficient to generate detectable aS-DOPAL oligomers. The result showed that the oligomers can affect the 
distribution of synaptic vesicles among the different pools. Furthermore, there is a strong decrease in the number 
of vesicles per synapse in the neurons treated with DOPAL, a reduction in the fraction of synaptic vesicles in the 
ready-releasable pool and an increase in the resting pool34. These observations, together with the fact that TIRFM 
detects vesicles at < 150 nm from the plasma membrane, suggest that aS-DOPAL oligomers may preferentially 
damage the vesicles ready to be released at the synapse, possibly because oligomer formation occurs in the sub-
cellular region where aS is known to participate in synaptic vesicle recycling. It should be mentioned that the 
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Figure 6. Permeabilization ability of aS-DOPAL oligomers in different membrane models. (a) Planar Lipid 
Membrane experiments showing the permeabilization ability of aS-DOPAL oligomers in lipid membranes 
constituted by POPC/CHO, and relative conductances distribution to characterize the pores formed. The same 
permeabilization was not present when the planar membranes were prepared with DOPE/DOPG. (b) POPC/
CHO SUVs mimicking synaptic vesicles composition and loaded with DA were permeabilized by aS-DOPAL 
oligomers and allowed the release of DA as measured by monitoring the Tyrosinase dependent Dopachrome 
formation at 505 nm (blue). When SUVs were not loaded with DA (red) or Tyrosinase was removed from 
the SUVs solution in the presence of aS-DOPAL oligomers (green), there was no formation of Dopachrome. 
When only Tyrosinase was added to the DA loaded SUVs (black), a small increase in the measured absorbance 
was observed probably because of DA leaking. (c) Confocal images of aS-DOPAL oligomers (red) localized 
at the plasma membrane (green) of BE(2)-M17 cells. (d) Permeabilization of BE(2)-M17 cells by aS-DOPAL 
oligomers as measured by propidium iodide after 2 and 8 hours treatment. (e) CD measurement of monomeric 
aS and aS-DOPAL oligomers alone and in the presence or absence of POPC/CHO or DOPE/DOPG SUVs show 
that aS-DOPAL oligomers can acquire an alpha-helical structure only in the presence of SDS which is able to 
disaggregate large non-covalent oligomers. (f) AFM images of aS-DOPAL oligomers performed on POPC/CHO 
lipid monolayer in liquid show that they present the annular shape previously observed by TEM by us and for 
other aS oligomeric species by others.
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chemical modifications of aS by DOPAL may also hinder SNARE complex assembly18, a proposed physiological 
function of aS. Therefore, reducing the amount of functional aS at the synapse may affect the number of synaptic 
vesicles belonging to the different pools and their recycling.
The proposed mechanism by which aS-DOPAL oligomers affect synaptic vesicles, implies their permeabi-
lisation. This permeabilisation process was investigated in vitro to analyse all the processes involved including: 
Lys modification by DOPAL, oligomers formation, oligomers-membrane interaction in relation to membrane 
composition and selectivity of the released species. Interestingly, aS-DOPAL oligomers share some structural 
characteristics with other aS oligomers formed in vitro36–38, as measured by TEM and AFM. The more detailed 
analysis was obtained from image reconstruction of cryoTEM images and it clearly outlines a pore like structure39. 
Here, in addition to the TEM images that are coherent with previously reported morphologies, we directly 
observed a pore-like structure by AFM upon deposition of aS-DOPAL oligomers on cholesterol-containing lipid 
membranes. These structural hints lead to the hypothesis that aS-DOPAL oligomers could be able to permea-
bilise artificial membranes, as previously suggested for other aS oligomer by this research group43 and others41. 
The aS-DOPAL oligomers pore-forming ability was proved in a PLM experiments and in an in vitro model for 
synaptic vesicles. Interestingly, it was observed that aS-DOPAL oligomers permeabilization occurs only when the 
membrane contained cholesterol, and the same pores did not form in the presence of unmodified monomeric aS, 
which was shown to mainly bind and permeabilise negatively charged lipid membrane42. The observed require-
ment of cholesterol, recently substantiated for other aS oligomers44, and the fact that the membranes used were 
uncharged, suggest that these oligomers may be more prone to damage membranes with composition similar to 
those of synaptic vesicles45. The aS-DOPAL oligomers were also shown to co-localize at plasma membrane when 
used to treat BE(2)-M17 cells, hinting again at the binding of the oligomers to physiological membranes. The 
treatment of BE(2)-M17 neuronal cells with oligomers lead to cell permeabilisation, suggesting that the effect 
observed in vitro also occurs on live cells.
An important piece of information which emerged from the in vitro permeabilisation experiments is that DA 
can easily permeate out of vesicles in the presence of aS-DOPAL oligomers. This implies a self-amplifying mech-
anism, in which a few molecules of cytoplasmic DOPAL in the presence of aS generate oligomers. These in turn 
trigger the release of further DA, which at the neutral cytoplasmic pH could be either oxidized or converted to 
DOPAL, which will generate further aS-DOPAL oligomers. Given that DA neurons, wherein DOPAL may accu-
mulate, are the neurons mainly affected in PD, these aS-DOPAL oligomers could in part account for the specific 
death of this class of neurons in PD. Interestingly, also other endogenous aldehydes were shown to covalently 
modify aS (recently reviewed in Plotegher & Bubacco27) and form oligomers that may be toxic, although the 
details of the mechanisms of toxicity are scarce. To make things worse, cytosolic ALDH, a detoxifying enzyme, has 
been reported to be downregulated in brains of PD patients7 and the DA neuronal population lacking the enzyme 
has been reported to be particularly vulnerable to neurodegeneration and aS aggregation8. Besides aS-DOPAL 
oligomers formation, aS Lys modification itself can be responsible for toxicity mechanisms in neurons. aS Lys 
residues are essential for the capacity of aS to bind to lipid membranes46,47 and their modification may cause an 
increase in the cytoplasmatic fraction of aS. A second direct consequence of aS Lys modification is a decreased 
capacity for aS to be ubiquitinated, SUMOylated, and acetylated, with the potential to impair the complex sig-
nalling pathways associated to these modifications27. In this context, the data obtained in vitro by MS and HSQC 
identify several target Lys residues, likely leading to more than one toxicity mechanism. The discrepancy between 
the data previously published by Follmer et al.31 and the results presented here in term of aS Lys modifications 
in vitro are likely due to the differences in the preparation of the sample. On the contrary, the differences among 
aS Lys found to be modified in cells and those modified in vitro may be due to the different conformation of aS 
monomers in cells, which may affect DOPAL reactivity toward aS Lys26. Another possibility is that the difference 
is due to the contribution of reducing species present in the cytoplasm and to other cellular mechanisms that clear 
DOPAL-modified aS22. Moreover, only monomeric aS modified by DOPAL (band at about 50 kDa) was collected 
from cells, and it seems likely that the digestion of monomeric aS modified by DOPAL may lead to the detection 
of more modified residues, because of an increased efficiency in the pepsin activity compared to the digestion of 
aS-DOPAL oligomers. This may also explain why there are more similarities between the modified Lys found in 
the aS-DOPAL monomers derived from cells and those found in the analysis of aS-DOPAL monomers obtained 
in vitro by Follmer et al.31. To conclude, the presence of aS-DOPAL oligomeric permeabilising species reported 
here have to be verified in PD patients, then further studies should focus on understanding how to prevent the 
formation of aS-DOPAL oligomers, for example by enhancing ALDH activity or expression level, by developing 
an immunotherapy against aS-DOPAL oligomers, or by acting on the cellular conditions.
Methods
Recombinant alpha-synuclein purification. Human aS cDNA was subcloned into the pET28a plasmid 
(Novagen) as previously described48.
Protein was then expressed in E. coli BL21(DE3) strain and aS was recovered from the periplasm by osmotic 
shock. The sample was then boiled for 10 minutes and the soluble fraction, containing the protein, was subjected 
to an ammonium sulfate precipitation (two step, respectively 35% and 55% of saturation). The pellet was then 
resuspended, dialyzed against deionized water, loaded into a 6 ml Resource Q column (Amersham Biosciences) 
and eluted with a 0–500 mM linear gradient of NaCl. Fractions corresponding to aS were collected, dialyzed 
against deionized water and lyophilized.
Synthesis of DOPAL. DOPAL was synthesized by rearrangement of epinephrine, following the method by 
Robbins49. The product was characterized by means of NMR spectroscopy using a Bruker AVANCE 400 spec-
trometer. The purity of obtained DOPAL was confirmed through HPLC by using a Jasco MD-1510 instrument 
with spectrophotometric diode array detection equipped with a Waters Symmetry C18 reverse-phase column 
www.nature.com/scientificreports/
1 2Scientific RepoRts | 7:40699 | DOI: 10.1038/srep40699
(250 × 4.6 mm). Elution was carried out starting with 0.1% trifluoroacetic acid in water for 5 min, followed by 
a linear gradient, in 40 min, to 100% acetonitrile with 0.1% trifluoroacetic acid. The flow rate was 0.8 mL/min.
In vitro modifications of alpha-synuclein by DOPAL. Samples of modified aS were prepared by add-
ing 1.25 mM DOPAL to 67 or 300 μ M aS solution in 50 mM phosphate buffer, pH 7.4. Two different set of sam-
ples have been prepared: with and without NaBH3CN as a reducing agent. In both cases reaction mixtures were 
allowed to react at 37 °C for 5 hours, protected from light. Samples aliquots were collected at different time points, 
loaded onto a gradient 4–20% SDS-PAGE and stained with Comassie blue. When the reaction was carried out in 
order to perform further experiments, the final reaction product was extensively dialyzed against PBS to eliminate 
DOPAL non bound to aS.
Gel filtration analysis. Separation of different species of aS after DOPAL reaction was obtained by gel 
filtration using a SuperdexTM 200 10/30 GL column (GE Healthcare) connected to an ÄKTAprime plus (GE 
Healthcare) system. The column was equilibrated with PBS pH 7.4 and the flow rate was 0.5 ml/min.
TEM imaging on alpha-synuclein/DOPAL oligomers and alpha-synuclein fibrils. 15 μ l aliquots 
of the aS/DOPAL oligomers, obtained as previously described, or of aS fibrils were absorbed onto carbon-coated 
copper grid and a 0.05% uranyl acetate solution was used for negative staining. TEM pictures were taken on a 
Tecnai G2 12 Twin instrument (FEI Company, Hillsboro, OR, USA).
LC-MS/MS analysis of protein fragments. After 5 hours HCl was added to reach pH 1.3 and the mod-
ified aS was digested at 37 °C with pepsin. The amount of pepsin added was 2% (w/w) with respect to aS and the 
enzyme was allowed to react overnight. The same amount of pepsin was added again and the digestions were 
carried out for other 6 hours, before injecting in LC-MS/MS.
aS-EGFP protein was extracted from SDS-page gels after loading the cell lysate and running the gel. A band 
in correspondence of the molecular weight of the aS-EGFP protein was identified and cut. Pepsin digestion fol-
lowed as described above. Peptide fragments obtained by digestion of the different aS samples were separated and 
analyzed in automated LC-MS/MS mode using a LCQ ADV MAX ion trap mass spectrometer coupled with an 
automatic injector system Surveyor HPLC (Thermo Finnigan, San José, CA, USA) with a BioBasicTM C18 (5 μ m, 
150 × 2.1 mm) column. The elution was performed using 0.1% HCOOH in distilled water (solvent A) and 0.1% 
HCOOH in acetonitrile (solvent B), with a flow rate of 0.2 mL/min; elution started with 98% solvent A for 5 min, 
followed by a linear gradient from 98% to 55% A in 60 min. The MS/MS spectra obtained by CID were recorded 
with an isolation width of 2 Th (m/z), the activation amplitude was around 35% of ejection RF amplitude of the 
instrument. For the analysis of protein fragments, the mass spectrometer was set such that one full MS scan was 
followed by zoom scan and MS/MS scan on the most intense ion from the MS spectrum. To identify the residues, 
the acquired MS/MS spectra were automatically searched against protein database for aS or aS-EGFP using the 
SEQUEST® algorithm incorporated into Bioworks 3.1 software (Thermo Finnigan, San Jose, CA).
Alpha-synuclein/DOPAL HSQC-NMR. We incubated a sample of 15N labelled aS (160.5 μ M) produced 
as previously described40 in the presence of an equimolar amount of DOPAL (160.5 μ M) in PBS (pH 7.4) at room 
temperature for 30 days. The reaction was monitored by recording 15N-1H HSQC spectra of the mixture at 25 °C. 
The final spectra reported are the overlap of the 15N-1H HSQC spectra of aS sample in the absence of DOPAL 
and after 30 days of incubation with DOPAL at 10 °C. The spectra were recorded at lower temperature than the 
incubation temperature due to resolution issues. The NMR experiments were recorded with a Bruker FT NMR 
Avance III 600-MHz spectrometer equipped with a 5-mm CryoProbe QCI 1 H/19F-13C/15N-D quadruple reso-
nance, and a shielded z-gradient coil. The analysis of the spectra was performed using the CcpNMR software and 
the NMR assignment published in the BMRB (bmr16300.str) for the intrinsically unfolded aS.
Thioflavin T alpha-synuclein aggregation assay. Fibrillation assay for aS was set up in a 96-well 
black plate (Perkin Elmer) with flat black bottom. For the control samples, lyophilized protein was dissolved 
in PBS (10 mM sodium phosphate, 1.8 mM potassium phosphate pH 7.4 and 137 mM NaCl, 2.7 mM KCl) and 
passed through a 100 kDa MWCO centrifugal filter unit (Amicon® Ultra, Millipore) to retain unsolved aggre-
gates that can act as seeds. Protein concentration was determined using a calculated extinction coefficient (Abs 
0.1%) at 280 nm in water of 0.412 ml/(mg*cm); for the modified protein the concentration was referred to the 
alpha-synuclein before DOPAL reaction and filtration was avoided because reacted material was retained by the 
filter. For each protein were prepared 3 wells: each well contains 200 μ l of sample, constituted of 1 mg/ml (about 
70 μ M) protein, 20 μ M ThT, 0.05% sodium azide. The plate was sealed with MicroAmp® Optical Adhesive Film 
(Applied Biosystems® - Life technologies) to avoid evaporation and incubated into a thermostated orbital shaker 
(Talboys Professional Model 1000MP Microplate Shaker by Troemner) at 37 °C at 1000 rpm. Aggregation pro-
gression was monitored measuring ThT emission with a VICTOR™ X3 Multilabel Plate Reader (PerkinElmer) 
at indicated intervals of time. ThT fluorescence was measured with excitation at 450 nm and emission at 535 nm, 
with a measurement time of 0.1 s, a CW-lamp energy of 5000 and a small emission aperture.
Planar Lipid Membranes (PLMs) measurement. Solvent-free PLMs were prepared using equimolar 
1,2-dioleylphosphatidyl-glycerol (DOPG) and 1,2-dioleyl-phosphatidyl-ethanolamine (DOPE) or equimolar 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) and cholesterol suspended in pentane, as described 
in ref. 50. All experiments were started in symmetric conditions, using 5 mM Hepes, 100 mM KCl (pH 7.0) buffer 
and miniature magnetic stirrers to mix the solutions in both chambers. A defined voltage of typically + 100 mV 
was applied across the membrane. The aS/DOPAL oligomers were added to cis side in concentration ranging from 
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0.1 μ M to 1 μ M. The current across the bilayer was measured and the conductance G was determined using the 
relationship:
=G(pS) I(pA)/V(V),
where I is the current across the membrane and V the applied transmembrane potential.
Macroscopic currents were recorded by a patch clamp amplifier (npi, Tamm, Germany), filtered at 100 Hz, 
digitalized and acquired at 2 kHz by the computer using a DigiData 1322 A/D converter and pClamp software 
(Axon Instruments, Sunnyvale, CA). All the measurements were performed at 22 °C.
Preparation of Small Unilamellar Vesicles (SUVs). A mixture of 50% 1-palmitoyl-2-oleoyl-sn-glycero-3
-phosphocholine (POPC) and 50% 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate (POPA) or cholesterol were 
used for the preparation of SUVs. The lipids were dissolved in 1 mL of a 4:1 chloroform/methanol mixture, and 
the solutions were evaporated under vacuum at 4 °C in a glass test tube. The dry lipid film was suspended in 
50 mM sodium phosphate buffer (pH 7.4) to give a final concentration of 30 mM and mixed for 1 h above the 
melting temperature. The product of hydration was filtered through a large pore size (0.45 μ m) filter and, subse-
quently, extruded through a 50 nm pore filter.
When DA-loaded SUVs were needed, DA was suspended in phosphate buffer pH 5.8 to a final concentration 
of 100 mM. The dry lipid film was then suspended in the DA solution and SUVs extruded as previously described. 
SUVs were then washed using Sepharose resin to remove the residual DA and change the buffer to 5 mM HEPES 
100 mM KCl pH 7.0.
CD Experiments. CD measurements were carried out on a JASCO J-715 spectropolarimeter interfaced with 
a personal computer. The CD spectra were acquired and processed using the J-700 program for Windows. All 
experiments were carried out at room temperature using HELLMA quartz cells with Suprasil windows and an 
optical path length of 0.1 cm. All spectra were recorded in the wavelength range of 200–250 nm, using a band-
width of 2 nm and a time constant of 2 s at a scan speed of 50 nm/min. The signal:noise ratio was improved by 
accumulating 4 scans. Spectra were acquired with a 5 μ M solution of WT aSN in the presence of 50 mM phos-
phate buffer (pH 7.4) with or without 10 mM SDS or 4 mM SUVs. The same measurements were repeated with an 
amount of DOPAL oligomers supposed to be equivalent in terms of monomeric aS. Spectra are not normalised 
respect to the protein concentrations, because of difficulty on quantification of oligomeric species.
Dopamine release from SUVs detected by a Tyrosinase-based in vitro assay. To measure DA 
release from SUVs in the presence of aS/DOPAL oligomers, 50 μ l of DA-loaded SUVs were resuspended in 5 mM 
HEPES 150 mM KCl pH 7.0 with 0.2 μ M tyrosinase (specific activity 6450 U/μ M) to a final volume of 200 μ l and 
plated in a 96-well plate. Up to 20 μ M aS-DOPAL oligomers were added to the vesicles and monomeric aS and 
PBS buffer were used as controls. SUVs not loaded with DA were also used in the same experimental condi-
tions to exclude that the effect we measured was due to the experimental conditions or to the oligomers them-
selves. Dopachrome formation was measured at 505 nm with a plate reader (Molecular Devices UVmax Kinetic 
Microplate Reader).
AFM on lipid bilayer. Mica, glued to a metal disc, was freshly cleaved to obtain smooth surface. The lipid 
membranes were prepared by successive apposition of two 50–50% POPC:CHO (or EggPC:CHO) (Avanti Polar 
Lipids) monolayers on the mica (similarly to ref. 51) Protein was added at two different concentrations, 5 to 20 μg 
in about 75–100 μ l. After 30–60 minutes incubation at RT, samples were carefully washed and analyzed by AFM 
at 21 °C. An Asylum Research Cypher, equipped with a droplet tip holder was used to acquire AFM data in liquid 
environment. Olympus TR400 and BL-AC40 cantilevers were used in tapping mode, scanning the sample with a 
scan rate of ~1 Hz. Asylum provided software was used for data acquisition. Image analysis was performed with 
SPIP (v4.2.6.0), applying line-by-line height compensation.
HEK293T and BE(2)-M17 cells culture and transfection. HEK293T cells media was high glucose 
DMEM (Life Technologies) supplemented with 10% v/v FBS (Life Technologies), 50 U/ml penicillin and 50 mg/ml 
streptomycin (Life Technologies) and BE(2)-M17 cells media was DMEM/F12 (Life Technologies) with 10% 
v/v FBS and 50 U/ml penicillin and 50 mg/ml streptomycin. All the cells were cultured at 37 °C in 5% CO2. Cells 
were transfected with the plasmids aS-EGFP, aS-mCherry or their empty vector, respectively pEGFP-N1 and 
pmCherry-N1(Novagen). HEK293T were transfected with Polyethylenimine (PEI) in a 1:4 ratio with DNA (v/w), 
BE(2)-M17 with lipofectamine (Lipofectamine 2000, Invitrogen) in a 1:2 ratio with DNA (v/w).
Immunocytochemistry, propidium iodide and imaging. BE(2)-M17 cells were plated on glass cover-
slips at 3 × 105 cells/well, treated with 2 μ M aS-DOPAL oligomers for 8 hours and fixed with 4% PFA. Cells were 
then stained with antibodies against aS (BD Biosciences, 610787) and against the plasma membrane marker 
E-cadherin (Santa Cruz, SC-7870) and further counterstained with secondary antibodies (Thermo Fisher 
Scientific, Alexa Fluor 568 A11031 and Alexa Fluor 488 A11034, respectively), and Hoechst (Thermo Fisher 
Scientific) to visualize nuclei. Imaging was performed on Leica SP5 confocal microscope.
To measure cell permeabilization 120000 cells per well were plated in a 12-well plate. After 24 hours cells were 
treated with 2 μ M aS-DOPAL oligomers and then, after 1 hour and 7 hours cells were stained with 2 μ g/ml propid-
ium iodide (Termo Fisher Scientific, P3566) and imaged by a widefield inverted microscope (Leica DMI 4000B).
Synapto-pHluorin confocal and TIRF imaging and analysis. BE(2)-M17 were plated on glass covers-
lips at 3 × 105 cells/well, co-transfected with 2 μ g synapto-pHluorin and 2 μ g mCherry or aS-mCherry for 3 hours 
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by means of lipofection (Lipofectamine 2000, Invitrogen) and 24 or 48 hours after plating cells were treated with 
100 μ M DOPAL in Optimem. Confocal imaging was performed on Leica SP8 to confirm colocalization between 
mCherry/aS-mCherry and synapto-pHluorin. Cells were fixed in PFA 4% and counterstained with Hoechst 
(Invitrogen) to visualize nuclei.
Single-cell imaging under TIRF illumination was carried out on live cells at 1 frame per second for 40 sec-
onds in the continuous presence of Krebs (KRH) solution, 125 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.2 mM 
KH2PO4, 25 mM 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (buffered to pH 7.4) and 2 mM 
CaCl2 (Sigma Aldrich), at 37 °C with or without DOPAL 100 μ M at different time points. Up to eight cells were 
imaged on each coverslip in three independent experiments by means of an AxiObserver Z1 inverted microscope 
(Carl Zeiss Inc.) equipped with an Argon laser at 37 °C using a 100 × 1.45 numerical aperture (NA) oil immer-
sion objective. Green fluorescence was excited using the 488-nm laser line and imaged through a band-pass 
filter (Zeiss) onto a Retiga SRV CCD camera. TIRF images were analyzed using Image-Pro Plus Analyser Image 
Software (Media Cybernetics, Bethesda, MD, USA). A set of automated image processing macro/subroutines 
was developed on the basis of existing algorithms of the Image-Pro Plus Analyser software (nearest neighboring 
deconvolution, High Gaussian filtering). The resulting corrected images were then analyzed for selection and 
quantification of fluorescent spots according to their shapes, size and intensity. For each recorded cell image, the 
total number of vesicles, the average vesicle mobility and fluorescence intensity, the ratio between fixed (vesicles 
visible in at least 30 out of the 40 frames) and mobile vesicles and its associated standard deviation in each frame 
were calculated.
Primary neuronal cell cultures and DOPAL treatment. All animal procedures were performed fol-
lowing the guidelines issued by the European Community Council Directive 2010/63/UE and approved by Ethics 
Committee of the University of Padova (Project ID: 46/2012).
Neuronal cells were derived from postnatal mouse (P0-P1) brains (CD1 strain). Cerebral cortices were isolated 
and cells mechanically dissociated in EBSS (Sigma Aldrich). Cells were centrifugated, resuspended in Neuro basal 
media (Life Technologies) supplemented with 2% v/v of B27 supplement (Invitrogen), 0.5 mM L-glutamine (Life 
Technologies), penicillin (100 Units/ml) streptomycin (100 μ g/ml) and 2.5 μ g/ml fungizone (Life Technologies). 
Cells were then plated at 2 × 106 cells/well on poly-L-lysine (0.1 mg/ml, Sigma Aldrich) coated wells of a 6-well 
plate and cultured at 37 °C in 5% CO2. After 7 days half medium was replaced and the neuronal culture was 
maintained until day 14. At 14 days neuronal cells were treated for 14 hours with 20 μ M and 50 μ M DOPAL and 
processed for further experiments.
Western blotting and ABPA resin. HEK293T, BE(2)-M17 and neuronal cells were collected and 
lysed on ice in lysis buffer 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton, 2.5 mM Sodium 
Pyrophosphate, 1 mM beta-glycerophosphate, 1 mM sodium orthovanadate supplemented with protease cocktail 
inhibitor (P8340, Sigma). Protein concentration was determined by BCA assay (Pierce) and equal amounts of 
total protein were loaded. For ABPA resin (A8530 Sigma) pulldown, 50 μ g total protein were incubated with 50 μl 
of the resin overnight at 4 °C shaking. The resin was then pelleted, the supernatant removed and the resin was 
washed 2 times with PBS/acetronitrile (50:50) and finally with water. Protein was collected from the resin by add-
ing 20 μ l Laemmli buffer, loaded into 10% or 4–20% gradient SDS-PAGE and compared with the total lysate. aS 
detection was performed using antibodies against aS (Abcam, ab138501 for human cells and ab52168 for mouse 
neurons) and housekeeping proteins (beta-tubulin and HSP90) were detected using a loading control sample kit 
(OriGene, TA150046). Horseradish peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG were then used 
and immunoreactive proteins were visualized using enhanced chemioluminescence plus (ECL+ , GE Healthcare).
TEM imaging on vesicles and analysis. Control and DOPAL treated neurons were fixed with 2.5% glu-
taraldehyde in 0.1 M sodium cacodylate buffer pH 7.4 for 1 hour at 4 °C. Neurons were then postfixed with a 
mixture of 1% osmium tetroxide and 1% potassium ferrocyanide in 0.1 M sodium cacodylate buffer for 1 hour 
at 4° and incubated overnight in 0.25% uranyl acetate at 4 °C. After three water washes, cells were dehydrated in 
a graded ethanol series and embedded in an epoxy resin (Sigma-Aldrich). Ultrathin sections (60–70 nm) were 
obtained with an Ultrotome V (LKB) ultramicrotome, counterstained with uranyl acetate and lead citrate and 
viewed with a Tecnai G2 (FEI) transmission electron microscope operating at 100 kV. Images were captured with 
a Veleta (Olympus Soft Imaging System) digital camera. EM images have been processed on NIH ImageJ before 
performing the analysis on LoClust tool52. Single vesicle has been manually annotated and the distance to the 
active zone is expressed in nm.
Statistical analysis. Data analysis, frequency count and statistical analysis (ANOVA and t test) were per-
formed using OriginPro 8.0 or GraphPad Prism 5.0.
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